Newborn Screening (NBS) Sample Preparation: A Comprehensive Guide for Laboratory Professionals

Since Dr. Robert Guthrie pioneered large-scale dried blood spot (DBS) screening for phenylketonuria in the 1960s, this specimen type has remained the cornerstone of newborn screening programs [3]. Blood collected via heel puncture is applied directly to specialized filter paper cards creating a dried blood spot matrix that offers unique advantages for population-based screening [1]. The dried blood spot format enables simplified collection at the bedside, eliminates refrigeration requirements during transport, reduces biohazard concerns, and provides a stable specimen that can be archived for years for potential retesting.

The CLSI has developed the NBS01 standard which defines comprehensive requirements for dried blood spot collection, including specifications for filter paper composition, blood application technique, drying conditions, and transport procedures [4]. Filter paper quality for dried blood spot specimens must be assessed based on factors such as chromatographic performance, sample volume, and red blood cell concentration [5]. Additionally, the paper matrix must not contain substances that interfere with analytical methods. These carefully controlled properties allow laboratories to punch standardized discs from dried blood spots, typically 3.2 millimeters in diameter, and achieve reproducible blood volumes for quantitative analysis despite the apparent simplicity of the specimen format [6].

The pre-analytical phase encompasses all steps from blood collection through specimen arrival at the laboratory and represents a critical control point for ensuring screening quality. Proper timing of collection significantly impacts results, with the recommended window being 24 to 48 hours after birth [1]. Collection before 24 hours may produce false-positive elevations in phenylalanine, isovalerylcarnitine, and propionylcarnitine due to the metabolic transition from maternal support to autonomous metabolism, while late collection beyond 48 hours delays diagnosis and treatment initiation [7]. The CLSI provides detailed specimen collection guidelines for agencies to implement. These procedures emphasize warming the heel to promote blood flow, using single-use retractable lancets, applying sufficiently large blood drops to fully saturate the filter paper (visible on both sides), and allowing specimens to dry horizontally for 3 to 4 hours at room temperature in a clean environment [8]. 

Multiple pre-analytical factors influence newborn screening results and must be understood by both collection personnel and laboratory staff interpreting results. The CLSI guideline NBS03 specifically addresses screening considerations for preterm, low birth weight, and sick newborns, providing detailed guidance on how prematurity, nutrition, transfusions, and intensive care unit treatments affect specific analytes [9]. Gestational age and birth weight significantly influence biomarker concentrations, with premature infants, particularly those born before 33 to 34 weeks of gestation, exhibiting elevated levels of certain biomarkers [7]. Total parenteral nutrition dramatically alters amino acid and acylcarnitine profiles, producing false-positive elevations that can complicate result interpretation [10]. Transfusions mask hemoglobinopathies by introducing donor red blood cells and hemoglobin, making pre-transfusion collection essential when possible [10]. Specific medications, including antibiotics, administered to newborns may interfere with screening assays. The CLSI NBS01 standard includes comprehensive tables documenting maternal conditions (such as glutaric aciduria type I or medium-chain acyl-CoA dehydrogenase deficiency), newborn conditions (including septicemia, jaundice, and very low birth weight), and treatments known to interfere with newborn screening result reliability [4].

Additionally, specimen quality issues represent a major source of pre-analytical error. Insufficient blood volume from spots that fail to completely saturate the filter paper, layered application where multiple drops are applied to the same circle, contamination from alcohol that was not allowed to dry completely, or contact with hands or lotions all compromise analytical accuracy. Laboratories must implement rejection criteria and request recollection for inadequate specimens, despite the inconvenience to families. Poor-quality specimens can produce false-positive or false-negative results, which are far more harmful than the minor delay caused by recollection.

Maintaining specimen integrity from collection through analysis and long-term archival storage requires detailed attention to environmental conditions. Temperature and humidity represent the primary degradation factors affecting dried blood spot stability, with most newborn screening markers showing significant degradation at elevated temperatures and high humidity [11]. A comprehensive stability study examining 34 newborn screening markers found that 27 showed degradation primarily from high humidity exposure, while temperature had less impact unless combined with moisture [11]. At 37℃ with high humidity, seven critical markers, including biotinidase, succinylacetone, arginine, and several acylcarnitines, lost more than 90% of their initial levels within 30 days [11].

For optimal storage, specimens analyzed within days to weeks should be kept at 2 to 8℃, while those archived beyond one year should be stored at -20 to -80℃ for long-term preservation [12]. Room temperature stability varies widely by analyte, with some markers remaining stable for weeks while others degrade rapidly. Galactose-1-phosphate uridyltransferase (GALT) enzyme activity for galactosemia screening decreased more than 60% when specimens were stored at 37℃, for 32 days, highlighting the temperature sensitivity of enzymatic assays [13]. Laboratories should implement rigorous storage protocols that include packaging dried blood spot cards with desiccant packets immediately after the drying period is complete, storing specimens in sealed bags or containers with humidity indicator cards, minimizing heat exposure during transport, and tracking time from collection to laboratory receipt. 

Tandem mass spectrometry (MS/MS) revolutionized newborn screening by enabling simultaneous quantification of multiple biomarkers from a single dried blood spot punch, dramatically expanding the number of detectable conditions. The CLSI guideline NBS04 provides comprehensive protocols for MS/MS newborn screening, including detailed specifications for reagent preparation, specimen extraction, instrument calibration, quality control acceptance criteria, and result interpretation [14]. Amino acid and acylcarnitine profiling detects a range of metabolic disorders, including amino acid disorders (phenylketonuria, maple syrup urine disease, homocystinuria, tyrosinemia, citrullinemia), organic acidemias (methylmalonic, propionic, isovaleric, glutaric acidemia type I), and fatty acid oxidation disorders (medium- and very long-chain acyl-CoA dehydrogenase deficiencies, carnitine uptake defect [15]. 

The standard extraction protocol begins with punching a 3.2-millimeter disc from the dried blood spot into a 96-well microplate, allowing simultaneous processing of multiple specimens in a high-throughput format [15]. The addition of 100 to 200 microliters of extraction solution containing internal standards dissolved in methanol-water mixture initiates the extraction process [15]. These are added at the very beginning of sample preparation and serve several essential roles: they correct for matrix effects and ion suppression, adjust for variations in extraction efficiency between specimens, and allow for more accurate quantification. Some protocols incorporate derivatization steps, particularly for flow injection analysis methods. In these cases, the solvent is evaporated under a nitrogen stream, and n-butanol containing hydrochloric acid is added and heated to convert amino acids to their butyl ester derivatives [15]. This derivatization improves chromatographic behavior and mass spectrometry ionization efficiency for amino acids.

Modern newborn screening laboratories increasingly adopt liquid chromatography separation before MS/MS detection. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods offer significant advantages including chromatographic separation that reduces ion suppression from co-eluting matrix components, improved specificity through retention time confirmation, and the ability to analyze multiple compound classes in the same analytical run [16]. Reversed-phase C18 columns or hydrophilic interaction liquid chromatography (HILIC) columns separate amino acids and acylcarnitines and provide comprehensive metabolic profiling that enhances diagnostic specificity and reduces false-positive rates [16].

For sample preparation protocols requiring solvent removal, including derivatization procedures, solid-phase extraction cleanup, and concentration of dilute extracts, nitrogen evaporation represents the gold standard. Nitrogen evaporators direct a gentle stream of nitrogen gas over the sample surface, creating a dry, inert atmosphere that facilitates rapid solvent evaporation while preventing oxidation of labile analytes. Temperature control during evaporation is critical, with many protocols maintaining room temperature to 40℃ to prevent thermal degradation of heat-sensitive metabolites.  

Microplate nitrogen evaporators have become essential equipment in high-throughput newborn screening laboratories, enabling simultaneous processing of 96-well plates. The Organomation MICROVAP microplate evaporators are specifically designed to accommodate newborn screening applications, offering precise nitrogen flow regulation and uniform heating across all wells. These systems achieve complete evaporation typically within 30 to 60 minutes depending on initial solvent volume and type, allowing laboratories to process multiple batches daily while maintaining consistent quality.

The advantages of nitrogen evaporation over alternative concentration methods include gentle treatment that preserves analyte integrity, elimination of bumping or sample loss that can occur with vacuum concentration, precise temperature control that prevents overheating, and compatibility with a wide range of solvent systems. For derivatization protocols, complete solvent removal is essential before adding derivatization reagents to prevent dilution effects and incomplete reactions. The dried residues are reconstituted in small volumes, typically 50 to 200 microliters, of injection solvent compatible with LC-MS/MS systems. 

The addition of lysosomal storage diseases to the RUSP, beginning with Pompe disease in 2015, mucopolysaccharidosis type I in 2016, and continuing with additional conditions, required newborn screening laboratories to develop new sample preparation approaches based on enzyme activity measurement rather than metabolite quantification [18, 19]. 

The multiplex enzyme assay workflow begins with punching a 3.2-millimeter dried blood spot disc into microplate wells, followed by the addition of substrate cocktails containing synthetic fluorogenic or MS/MS-compatible substrates for four to six enzymes simultaneously [19]. These substrates consist of the natural enzyme substrate molecule linked to a tag that can be detected by mass spectrometry or fluorescence; when the enzyme is active, it cleaves the substrate, releasing a detectable product in proportion to total enzyme activity. Samples are then analyzed using MS/MS systems with multiple reaction monitoring to measure enzyme products, or by fluorimetry for fluorogenic substrates, enabling accurate measurement of enzyme activity. 

Congenital adrenal hyperplasia, primarily caused by 21-hydroxylase deficiency, is detected through measurement of elevated 17α-hydroxyprogesterone in dried blood spots [20]. Traditional immunoassay methods for 17α-hydroxyprogesterone suffer from significant cross-reactivity with other steroid metabolites, producing high false-positive rates [20]. LC-MS/MS methods for steroid profiling have dramatically reduced false positives while enabling simultaneous quantification to provide enhanced diagnostic specificity [20].

Steroid extraction from dried blood spots typically employs methanol or acetonitrile-based solvents. Following extraction, the solvent is evaporated under nitrogen stream to dryness, and the residue is reconstituted in a liquid chromatography-compatible mobile phase [21]. Reversed-phase C18 chromatography effectively separates the steroid panel, enabling calculation of steroid ratios that further improve diagnostic accuracy [20]. The 17α-hydroxyprogesterone to cortisol ratio may improve specificity compared to 17α-hydroxyprogesterone alone, and these analytical approaches appear promising for future advancements [20].

The addition of severe combined immunodeficiency screening through T-cell receptor excision circles (TREC) quantification and spinal muscular atrophy screening to the RUSP necessitated development of DNA extraction protocols optimized for dried blood spots. The CLSI guideline NBS06 specifically addresses newborn blood spot screening for severe combined immunodeficiency through TREC measurement, providing detailed protocols for DNA extraction, real-time quantitative PCR amplification, and result interpretation [22]. T-cell receptor excision circles are circular DNA molecules produced during normal T-cell development in the thymus; healthy newborns have approximately 1,000 TRECs per dried blood spot punch, while infants with severe combined immunodeficiency have undetectable or very low TREC levels due to absent or severely impaired T-cell production [23]. For routine TREC quantification by real-time PCR, many laboratories employ simplified extraction methods that balance DNA yield and purity with high throughput and low cost. The DNA extraction is followed by duplex real-time PCR that amplifies both the TREC sequence and a β-actin control gene to verify DNA quality and quantity; specimens with low or absent TRECs but adequate β-actin amplification are flagged as screen-positive requiring immediate follow-up [23].

Multiple DNA extraction methods have been evaluated for newborn screening applications, ranging from highly purified column-based extractions to simple boil preparation methods. The CDC compared nine extraction methods for next-generation sequencing applications targeting the cystic fibrosis transmembrane conductance regulator (CFTR) gene, examining both extraction quality and performance in library preparation [24]. Methods evaluated included Qiagen QIAamp DNA Micro Columns representing the gold standard with multiple wash steps and elution in buffer, Perkin Elmer NeoMDx Kit optimized for dried blood spots, simplified Qiagen Purification and Elution Solutions with abbreviated wash steps and 15-minute boil, Triton X-100 detergent-based buffers with 40-minute boil, and various single-step boil preparations [24]. The study found that all nine DNA extraction methods performed reasonably well for next-generation sequencing library preparations, demonstrating that high-throughput, cost-effective methods are viable for newborn screening molecular applications [24].

Solid-phase extraction (SPE) represents a powerful sample cleanup technique that removes matrix interferences causing ion suppression in mass spectrometry, thereby improving analytical sensitivity, precision, and accuracy. Solid-phase extraction uses solid adsorbent materials, available as cartridges, 96-well plates, or magnetic beads, to selectively retain or exclude compounds based on their chemical properties [26]. In SPE, two primary strategies are employed. In the bind-and-elute methods, target analytes are retained on the sorbent while interferants pass through, followed by washing and elution with a strong solvent [26]. In contrast, removal or pass-through methods allow analytes to flow through while matrix components, such as proteins, phospholipids, and salts, are retained on the sorbent [26].

While SPE has been widely used in clinical chemistry and toxicology, its application in routine newborn screening has been more limited due to throughput demands and the need for rapid turnaround times, although newer high-throughput formats are expanding its feasibility. The development of online solid-phase extraction integrated directly into LC-MS/MS systems has made cleanup more practical. Turbulent flow chromatography columns use high flow rates to create turbulent flow conditions where large molecules like proteins are rapidly washed to waste while small molecules (metabolites, steroids, enzyme assay products) are retained and then eluted onto the analytical column [27]. This online approach minimizes manual sample handling, reduces analysis time, improves reproducibility, and maintains high throughput, making it well suited for implementation in newborn screening laboratories while preserving the cleanup advantages of SPE [27].

Quality assurance represents an indispensable component of newborn screening laboratory operations, given the critical importance of accurate results and the population-scale scope of testing. The CDC’s NSQAP provides comprehensive quality assurance services to more than 670 newborn screening laboratories worldwide, including all state laboratories in the United States, laboratories in more than 86 countries, and 32 newborn screening test manufacturers [2]. The program distributes nearly one million dried blood spot reference materials annually, encompassing both quality control materials for daily monitoring and proficiency testing materials for performance evaluation [2].

Proficiency testing materials with unknown concentrations are distributed and participating laboratories analyze these materials following their standard operating procedures and submit results to the CDC for comparative peer analysis. Performance is evaluated against method-specific acceptance criteria, and laboratories showing results outside acceptable ranges receive technical consultation to identify and correct the source of discordance. This proficiency testing is required for certification and laboratory accreditation [2]. Daily quality control practice involves analyzing quality control materials alongside patient samples to monitor analytical system performance in real-time. The NSQAP provides target values and acceptable ranges for quality control materials, allowing laboratories to verify their method accuracy and precision against traceable standards [2].

The Association of Public Health Laboratories, through the NewSTEPs (Newborn Screening Technical assistance and Evaluation Program), complements the CDC's laboratory quality assurance by establishing quality indicators that track the process across the entire newborn screening system [28]. Five quality indicators specifically address follow-up performance, including percentage of eligible newborns not receiving screening, percentage of infants with no recorded final resolution, percentage requiring clinical diagnostic workup by disorder category, percentage with confirmed diagnosis, and percentage of missed cases [28]. State newborn screening programs provide quality indicator data to the NewSTEPs Data Repository for comparison of metrics against national and regional benchmarks, facilitating continuous quality improvement [28]. 

Establishing appropriate cutoff values that separate screen-positive from screen-negative newborns represents one of the most consequential decisions newborn screening programs make. The Association of Public Health Laboratories guidance document on cutoff determinations and risk assessment methods describes various approaches laboratories use [29]. Percentile-based cutoffs set thresholds at the 95th, 99th, or 99.9th percentile of the normal population distribution, with some programs implementing floating cutoffs that adjust daily based on batch median or mean [29]. Fixed cutoffs use absolute analyte concentration thresholds established by comparing affected patient samples to normal population distributions [29]. 

Multiple factors influence optimal cutoff selection and should be considered during both initial establishment and periodic review. Age at blood collection significantly affects metabolite concentrations, with specimens collected before 24 hours showing elevations in some metabolites and lower levels in others. Gestational age and birth weight also substantially impact biomarker levels, with premature infants showing elevations in some metabolites. Population-specific reference ranges may also differ by race and ethnicity. These factors should be carefully considered when establishing and refining cutoffs [29].

Second-tier testing strategies resolve many screen-positive cases using the same initial dried blood spot, avoiding patient recall and reducing parental anxiety while dramatically improving positive predictive value [29]. These approaches analyze additional biochemical markers or perform molecular genetic testing on residual dried blood spot material from specimens that screen positive on first-tier testing [29]. 

Nontargeted metabolomics represents an exciting frontier that extends beyond the limited panel of analytes measured in routine newborn screening to comprehensively profile thousands of metabolites, enabling biomarker discovery, detection of unanticipated disorders not on the RUSP, and improved phenotype prediction. Sample preparation optimization for dried blood spot metabolomics has identified that overnight gentle agitation extraction at 2 to 8℃ with 80% methanol followed by nitrogen evaporation and reconstitution enables profiling of approximately 2,000 metabolites [30]. Another method using a hydrophilic interaction liquid chromatography provides comprehensive coverage of newborn screening-relevant pathways by retaining polar amino acids, acylcarnitines, nucleotides, and carbohydrates while also capturing lipid species [30]. 

Another area of advancement is in automated sample preparation systems. These systems integrate robotic dried blood spot punching, automated internal standard spraying, inline extraction and derivatization, and direct coupling to LC-MS/MS systems [31]. They are designed to reduce labor costs, improve traceability, enhance standardization, and ensure compliance with regulatory standards [31]. These fully automated workflows eliminate manual pipetting errors, reduce contamination risk, and free highly trained laboratory personnel to focus on result interpretation and method development rather than repetitive manual tasks.

Sample preparation represents far more than a technical procedural requirement in newborn screening. From blood collection by heel puncture through extraction, cleanup, and concentration, proper sample handling determines whether affected newborns are identified in time for intervention. The CLSI standards for dried blood spot collection (NBS01), tandem mass spectrometry screening (NBS04), severe combined immunodeficiency screening (NBS06), and preterm infant considerations (NBS03) provide the evidence-based framework that newborn screening laboratories worldwide rely upon to implement consistent, high-quality practices. Additionally, the Centers for Disease Control and Prevention Newborn Screening Quality Assurance Program demonstrates the critical importance the public health community places on ensuring sample preparation and analytical quality. By providing certified reference materials, proficiency testing, and technical consultation, the program helps laboratories maintain the accuracy required for screening millions of asymptomatic newborns to identify the relatively small number affected by rare but treatable conditions. 

As newborn screening programs expand to include additional conditions and adopt advanced technologies, the complexity and sophistication of sample preparation continues to increase. Laboratory professionals must maintain a deep understanding of the biochemical principles underlying each sample preparation step and continuously evaluate new technologies and methods that may enhance screening performance. The success of newborn screening depends fundamentally on the often-unseen work of laboratory professionals expertly preparing samples according to rigorous standards. By understanding the critical importance of proper sample preparation and implementing best practices throughout the workflow, newborn screening laboratories fulfill their mission of giving every newborn the best possible chance for a healthy life.

Citations:

1. https://www.ncbi.nlm.nih.gov/books/NBK558983/
2. https://www.cdc.gov/laboratory-quality-assurance/php/newborn-screening/index.html
3. https://newbornscreening.hrsa.gov/about-newborn-screening
4. https://clsi.org/about/press-releases/clsi-publishes-new-edition-of-nbs01-dried-blood-spot-specimen-collection-for-newborn-screening/
5. https://www.sciencedirect.com/science/article/pii/S0022316622138526?via%3Dihub
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7548895/
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7854909/
8. https://www.in.gov/health/gnbs/information-for-providers/screening-cards/#:~:text=The%20submitter%20is%20responsible%20for,Do%20not%20apply%20a%20bandage
9. https://clsi.org/shop/standards/nbs03/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC9478258/#:~:text=to%20a%20diagnosis.-,1,4%E2%80%936
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4557772/
12. https://www.nature.com/articles/s41598-024-82041-2
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4547523/
14. https://clsi.org/shop/standards/nbs04/
15. https://www.agilent.com/Library/applications/5990-6036en_lo%20CMS.pdf
16. https://pubs.acs.org/doi/10.1021/acs.analchem.4c06061
17. https://www.organomation.com/products/nitrogen-evaporators/microvap/microplate-evaporator
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10123615/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC5515486/
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6340850/
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC11294408/
22. https://clsi.org/shop/standards/nbs06/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3294074/
24. https://stacks.cdc.gov/view/cdc/89154
25. https://www.organomation.com/what-is-solid-phase-extraction-spe
26. https://chem.libretexts.org/Bookshelves/Analytical_Chemistry/Supplemental_Modules_%28Analytical_Chemistry%29/Analytical_Sciences_Digital_Library/Contextual_Modules/Sample_Preparation/03_Solid-Phase_Extraction
27. https://www.thermofisher.com/blog/analyteguru/automated-lc-ms-sample-cleanup-using-turbulent-flow-chromatography/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395728/
29. https://www.aphl.org/programs/newborn_screening/Documents/Cutoff-Determinations-and-Risk-Assessment-Methods.pdf
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC12474595/
31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7548895/